| scholarly article | Q13442814 |
| P50 | author | Ramón Cacabelos | Q66809646 |
| Rocio Martinez-Bouza | Q121434345 | ||
| P2860 | cites work | A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk | Q24336362 |
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease | Q24656574 | ||
| Genetic contribution to variable human CYP3A-mediated metabolism | Q28212042 | ||
| Deciphering the genetic basis of Alzheimer's disease | Q28216056 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway | Q33328700 | ||
| Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. | Q33359590 | ||
| Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice | Q33359744 | ||
| Association of GSK3B with Alzheimer disease and frontotemporal dementia | Q33737139 | ||
| High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain | Q33957039 | ||
| Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. | Q34148953 | ||
| Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease | Q34489699 | ||
| Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics | Q34965949 | ||
| Pharmacogenomics for the treatment of dementia | Q35009345 | ||
| Clinical proteomics: present and future prospects. | Q35053674 | ||
| Pharmacological treatment of Alzheimer disease: from psychotropic drugs and cholinesterase inhibitors to pharmacogenomics. | Q35178008 | ||
| The application of functional genomics to Alzheimer's disease | Q35207554 | ||
| Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences | Q35238375 | ||
| Cerebrovascular risk factors in Alzheimer's disease: Brain hemodynamics and pharmacogenomic implications | Q35540359 | ||
| Molecular genetics of schizophrenia: a critical review. | Q35590435 | ||
| Pharmacogenetics and drug development: the path to safer and more effective drugs | Q35889605 | ||
| Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. | Q35925154 | ||
| Pharmacogenomics and therapeutic prospects in Alzheimer's disease | Q36273420 | ||
| The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. | Q36367098 | ||
| Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). | Q36504889 | ||
| A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease | Q36565633 | ||
| Pharmacogenetics and pharmacogenomics: development, science, and translation | Q36583761 | ||
| Molecular genetics of bipolar disorder and depression. | Q36713347 | ||
| Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics | Q36956849 | ||
| Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression. | Q36980322 | ||
| Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease | Q37031522 | ||
| Association between SORL1 and Alzheimer's disease in a genome-wide study | Q37074629 | ||
| Pharmacogenomics and therapeutic prospects in dementia | Q37111344 | ||
| Neuroprotective effects of the Alzheimer's disease-related gene seladin-1. | Q37259867 | ||
| The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety | Q37299239 | ||
| Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease | Q37337050 | ||
| Pharmacogenomics and therapeutic strategies for dementia | Q37592250 | ||
| The selective Alzheimer's disease indicator-1 gene (Seladin-1/DHCR24) is a liver X receptor target gene | Q39936153 | ||
| Molecular genetics of Alzheimer's disease and aging | Q40351678 | ||
| The metabolism and excretion of galantamine in rats, dogs, and humans | Q43957720 | ||
| Memantine in moderate-to-severe Alzheimer's disease | Q44388745 | ||
| Apolipoprotein E polymorphism and brain morphology in mild cognitive impairment | Q48888248 | ||
| Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer's disease | Q49020243 | ||
| Genetic association between SORL1 polymorphisms and Alzheimer's disease in a Japanese population. | Q53296261 | ||
| Promoter polymorphisms modulating HSPA5 expression may increase susceptibility to Taiwanese Alzheimer's disease. | Q53296857 | ||
| Pharmacogenomics in Alzheimer's disease | Q80966591 | ||
| P433 | issue | 5 | |
| P921 | main subject | dementia | Q83030 |
| genomics | Q222046 | ||
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 566-576 | |
| P577 | publication date | 2010-08-16 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | Genomics and pharmacogenomics of dementia | |
| P478 | volume | 17 |
| Q36919235 | Cognitive decline and dementia in the oldest-old |
| Q50636887 | Effect of APOE and CHRNA7 genotypes on the cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. |
| Q38225708 | Epigenetic drug discovery for Alzheimer's disease |
| Q97420369 | Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy |
| Q39512782 | Genetic testing in combination with preventive donepezil treatment for patients with amnestic mild cognitive impairment: an exploratory economic evaluation of personalized medicine |
| Q35852564 | Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics |
| Q42073963 | Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid-β vaccine |
| Q36243522 | Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains |
| Q50683288 | Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease. |
| Q64103286 | Sirtuins in Alzheimer's Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics |
| Q94351634 | The New Editorial Team at CNS Neuroscience and Therapeutics |
Search more.